Announces differences between cumulative second-quarter results and the second-quarter forecasts for the fiscal year ending March 2027. Revises consolidated full-year earnings forecasts upward \u2014 revenue, operating income, ordinary income, and net income attributable to owners of parent \u2014 driven by strong performance in the Electronics segment. Medical, Pharmaceuticals, and ICT&S forecasts remain unchanged. Dividend forecast is unchanged.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4626","jir_company_name":"Taiyo Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4626-20261106-02.pdf","jir_short_summary":"Announces differences between cumulative second-quarter results and the second-quarter forecasts for the fiscal year ending March 2027. Revises consolidated full-year earnings forecasts upward \u2014 revenue, operating income, ordinary income, and net income attributable to owners of parent \u2014 driven by strong performance in the Electronics segment. Medical, Pharmaceuticals, and ICT&S forecasts remain unchanged. Dividend forecast is unchanged.","jir_summary":"### Key Points of Earnings Revision\nPerformance in the Electronics segment for the second quarter exceeded expectations due to the yen depreciation and price revisions. Based on the second-quarter results, the full-year forecast has been revised upward: revenue to 152,500 million yen, operating income to 39,600 million yen, ordinary income to 39,700 million yen, and net income attributable to owners of parent to 29,600 million yen. Net income per share has been raised to 266.01 yen. Forecasts for Medical, Pharmaceuticals, and ICT&S remain unchanged.\n\n### Segment Impacts and Outlook\nBy segment, the Electronics business is expected to contribute significantly to revenue, exceeding the previous fiscal results. The full-year dividend forecast remains as announced on April 30, 2026. Taking into account the gain on sale of investment securities recorded as a special gain in the second quarter, the overall earnings forecast has been revised rather than left unchanged. Medical, Pharmaceuticals, and ICT&S retain their current forecasts.","jir_financial_highlights":"Revenue: 78,480 million yen (Revised upward from previous forecast of 75,900 million yen)\nOperating Income: 22,230 million yen (Revised upward from previous forecast of 18,900 million yen)\nOrdinary Income: 22,739 million yen (Revised upward from previous forecast of 19,200 million yen)\nNet Income Attributable to Owners of Parent: 17,305 million yen (Revised upward from previous forecast of 13,100 million yen)\nNet Income Per Share: 155.52 yen (Revised upward from previous forecast of 117.73 yen)","jir_category":"","jir_hashtags":"#TaiyoHoldings, #Earnings, #FullYearRevision, #Electronics, #CurrencyImpact","jir_key_figures":"Revenue: 152,500 million yen (an increase of 3,400 million yen from the previous forecast of 149,100 million yen)\nOperating Income: 39,600 million yen (an increase of 3,200 million yen from the previous forecast of 36,400 million yen)\nOrdinary Income: 39,700 million yen (an increase of 3,400 million yen from the previous forecast of 36,300 million yen)\nNet Income Attributable to Owners of Parent: 29,600 million yen (an increase of 4,200 million yen from the previous forecast of 25,400 million yen)\nNet Income Per Share: 266.01 yen (revised upward from the previous forecast of 228.26 yen)","jir_meta_title":"Taiyo Holdings Co., Ltd. \u2014 Revised FY2027 Full-Year Forecast Following Q2 Results\uff5cUpward Revision Driven by Electronics","jir_meta_description":"Taiyo Holdings Co., Ltd. announced revisions to its full-year earnings forecast for the fiscal year ending March 2027 after Q2 results. Revenue and profits were revised upward due to strong performance in the Electronics segment. Medical, Pharmaceuticals, and ICT&S forecasts remain unchanged; dividend forecast maintained.","jir_og_title":"Taiyo Holdings Co., Ltd. Revises Full-Year Forecast Upward\uff5cElectronics Segment Strong","jir_og_description":"Driven by strong Electronics performance, Taiyo Holdings Co., Ltd. raised its full-year forecast. Key metrics revised to revenue 152,500 million yen and net income per share 266.01 yen. Dividend unchanged.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/7\\\",\\\"2026\/9\\\",\\\"2027\/3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[75800,78480,?,152500],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/7\\\",\\\"2026\/9\\\",\\\"2027\/3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[18900,22230,?,39600],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Revenue by Segment\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Electronics\\\",\\\"Medical & Pharmaceuticals\\\"],\\\"datasets\\\":[{\\\"data\\\":[108400,37500],\\\"backgroundColor\\\":[\\\"#36a2eb\\\",\\\"#ff6384\\\"]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Margin by Segment\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Electronics\\\",\\\"Medical & Pharmaceuticals\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[363? , 4000],\\\"backgroundColor\\\":[\\\"#36a2eb\\\",\\\"#ff6384\\\"]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Forecast vs Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Revenue\\\",\\\"Operating Income\\\",\\\"Ordinary Income\\\",\\\"Net Income Attributable to Owners of Parent\\\",\\\"Net Income Per Share\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Forecast\\\",\\\"data\\\":[149100,36400,36300,25400,228.26],\\\"backgroundColor\\\":\\\"#36a2eb\\\"},{\\\"label\\\":\\\"Actual\\\",\\\"data\\\":[152500,39600,39700,29600,266.01],\\\"backgroundColor\\\":\\\"#4bc0c0\\\"}]}},\\\"options\\\":{}}\"}]","ir_related_company":7826,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-142503","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n